Amarin Plc(NASDAQ) AMRN

Amarin Corporation plc helps people lower heart disease risks. Its prescription medicine helps adults reduce high fat levels in the blood. This treatment works with healthy diets to improve long-term heart health.

What Amarin Brings to Pharmacies

• VASCEPA: Prescription omega-3 fatty acid used to reduce very high triglyceride levels in adult patients; known as VAZKEPA in Europe.
• Cardiovascular Risk Reduction: Supplemental therapy for high-risk patients on statins to prevent major heart events like heart attacks or strokes.
• Collaborative Drug Development: Research and marketing of drug products derived from omega-3 acid in partnership with other pharmaceutical firms.

Expanding Across Global Borders

• Entered a long-term license agreement with Recordati in June 2025 to manage sales in 59 European countries.
• Established partnerships with seven commercial companies to reach markets in China, Canada, Australia, and the Middle East.
• Secured a European patent in April 2024 that extends market exclusivity for its main product until 2039.
• Obtained national reimbursement approvals in countries like Spain, Italy, and the Netherlands between 2023 and 2025.

How the Company Stays Competitive

Amarin manages a diverse supply chain with multiple approved manufacturers to prevent any inventory shortages. The company also maintains a strong scientific foundation with its icosapent ethyl treatment recognized in over 70 medical guidelines.

Checking the Financial Pulse

• Total revenue, net was $42.2 million in the three months ended June 30, 2026, down 42% year over year.
• U.S. net product revenue reached $67.9 million during the six months ended June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $314.9 million as of June 30, 2026.
• Gross margin on product sales was 34% for the six-month period ended June 30, 2026.
• Selling, general, and administrative expenses fell 42% to $43.3 million during the six months ended June 30, 2026.

The Road Ahead

Amarin has transitioned from a direct sales model to a partnership-driven strategy to navigate U.S. generic competition. This shift focuses on international expansion and operational efficiency to maintain its position in the heart health market.